Revvity stock (US76155R1086): Q1 earnings beat with $1.06 EPS

Revvity reported Q1 2026 earnings of $1.06 per share on May 5, topping estimates by $0.04. Shares trade at $96.67 on NYSE amid $10.81B market cap and new $1B buyback.

Revvity Inc. released its Q1 2026 earnings on May 5, 2026, posting adjusted EPS of $1.06, which beat the consensus estimate of $1.02 by $0.04, according to MarketBeat as of May 5, 2026. The NYSE:RVTY stock traded at $96.67 on May 14, 2026, up 1.75% intraday with a market cap of $10.81 billion.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Revvity Inc.
• Sector/industry: Life sciences and diagnostics
• Headquarters/country: United States
• Core markets: US, Europe, Asia
• Key revenue drivers: Technology solutions for discovery and diagnostics
• Home exchange/listing venue: NYSE (RVTY)
• Trading currency: USD

Revvity: core business model

Revvity provides technology-enabled solutions for life sciences, diagnostics, and applied markets worldwide. The company focuses on discovery and diagnostics products that support research, development, and clinical applications in healthcare and biotech sectors. Its portfolio includes instruments, reagents, software, and services used in drug discovery, genetic screening, and bioanalysis.

Listed on the NYSE under ticker RVTY, Revvity serves academic institutions, pharmaceutical firms, and diagnostic labs, with significant exposure to the US market where biotech innovation drives demand. The firm's solutions enable advancements in precision medicine and therapeutic development, key areas for US investors tracking healthcare growth.

Main revenue and product drivers for Revvity

Revvity generates revenue primarily from its life sciences and diagnostics segments. Key products include mass spectrometry systems, genetic analysis tools, and imaging solutions. In Q1 2026, the company demonstrated resilience with EPS beating expectations, signaling steady demand in core areas despite market fluctuations, per MarketBeat as of May 5, 2026.

Applied markets contribute through consumables and services tied to long-term customer contracts. US-based pharma R&D spending remains a major driver, positioning Revvity favorably amid rising investments in biologics and diagnostics relevant to American healthcare providers.

Industry trends and competitive position

The life sciences tools sector benefits from increased R&D in gene therapy and personalized medicine. Revvity competes with firms like Thermo Fisher and Danaher, holding a niche in high-throughput screening and endocrine diagnostics. Recent FDA-cleared products bolster its pipeline, enhancing US market relevance.

Why Revvity matters for US investors

Revvity's NYSE listing and focus on US-centric biotech innovation make it a direct play on American healthcare spending. With tools integral to FDA-regulated drug development, the company aligns with domestic policy shifts favoring advanced diagnostics and research funding.

Conclusion

Revvity's Q1 earnings beat highlights operational strength in a competitive sector, supported by a $1 billion share repurchase authorization from October 2025. While shares hover near $96.67 amid a hold consensus rating, the firm's diagnostics expansion and US market ties offer visibility into life sciences trends. Investors monitor upcoming catalysts like further product clearances.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.